General Inception
General Inception is a deep tech venture studio that co-founds biotech companies with scientific founders, operating a portfolio of 13+ companies across engineered biology, life sciences tools, diagnostics, and therapeutics, enhanced by AI and quantum-mechanics drug discovery platforms.
- Company typePrivate
- Founded2020
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What General Inception does
General Inception is a deep tech venture studio founded in 2020 and headquartered in Palo Alto, California, that operates as a business co-founder for science-based companies. The studio partners with technical and scientific founders across engineered biology, life science tools and diagnostics, and therapeutics, guiding ventures from idea through seed investment and beyond via an "Igniter" model that supplies legal, financial, business strategy, and operations support alongside access to talent, customers, and institutional capital. As of recent disclosures, the studio maintains a portfolio of more than 13 biotech companies and operates with a team of 11-50 employees plus more than 20 Executives-in-Residence, with regional teams in France, Belgium, the Netherlands, and the United Kingdom through the Igniter Europe program launched in April 2024.
The studio's technology stack is anchored by two AI- and computational-driven platforms acquired or allied over 2023-2024. Enable Medicine (acquired December 2024) provides the Enable Atlas, a multimodal biological dataset indexed across billions of cells and thousands of patient data sets, and applies generative AI to search disease maps for novel drug targets and indications. Pharmacelera, under a 2023 strategic alliance, contributes a quantum mechanics and AI drug discovery platform that has completed more than 100 projects with repeat business from three big pharma clients. The studio's broader portfolio includes Resolve M Therapeutics (pro-resolution immunology, created with Johnson & Johnson Innovation – JJDC), Ennovate Pharma (autoimmune and inflammatory therapeutics), SonoNeu (sonogenetics, with up to $41.3M in ARPA-H funding), Biocellis (bioluminescence diagnostics with Institut Pasteur), Surf Therapeutics (ultrasound neuromodulation), and Planet Smart (biodegradable superabsorbent polymers).
General Inception's revenue model combines portfolio company equity appreciation with services revenue. Fractional services including Transformation Services, Fractional Finance, and Lab Services (GIL'S) originated as internal portfolio support and have expanded to external clients, while investors back the studio directly; named backers include Genoa Ventures, Hughes Ventures, Northpond Ventures, OMX Ventures, Paladin Capital Group, and Vertical Venture Partners. Pricing is not publicly disclosed and the studio does not report standalone revenue figures, with returns materially tied to portfolio company outcomes rather than product sales.
General Inception firmographics
Firmographics- Name
- General Inception
- Legal name
- General Inception
- Website
- https://generalinception.com/
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- General Inception is a deep tech venture studio that co-founds biotech companies with scientific founders, operating a portfolio of 13+ companies across engineered biology, life sciences tools, diagnostics, and therapeutics, enhanced by AI and quantum-mechanics drug discovery platforms.
- Ownership category
- akta.pro rank
General Inception industry classification
Industry- Product category
- Venture Studio / Biotech Incubation Services
- NAICS
- Portfolio Management and Investment Advice (523940), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169), Scientific Research and Development Services (5417)
- SIC
- Services-Management Consulting Services (8742), Investment Advice (6282)
- akta.pro primary industry
- Venture Studios / Company Builders (FSANAAAH)
Keywords
Where General Inception is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices8 records
Markets served
General Inception business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Portfolio Company Returns: General Inception operates as a venture studio that creates and scales biotech companies. Revenue is generated through successful portfolio company exits and equity appreciation.
- Services Revenue: Fractional services including Transformation Services, Fractional Finance, and Lab Services are offered to portfolio companies and external clients. Services began as internal support but expanded to serve external customers.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
General Inception product offering
Product offeringCore offering
General Inception operates as a Deep Tech Venture Studio that co-founds science-based companies with extraordinary technical founders, providing business co-founding services that span talent sourcing, customer introductions, and funding access from idea through seed investment and beyond. Complementing venture creation, GI sells discrete professional services — Transformation Services (fractional executive leadership for turnarounds and growth), Fractional Finance (CFO-level finance and accounting support), and Lab Services / GIL'S (R&D operations across fibrosis, oncology, inflammation, and autoimmune disease) — to portfolio companies and external clients.
Product overview
General Inception is a Deep Tech Venture Studio that operates as a business co-founder, partnering with scientific founders to build biotech companies. Rather than a single product, GI offers a portfolio of venture-building services (Transformation Services, Fractional Finance, Lab Services/GIL'S, Program Development Manager) and the Igniter Europe initiative for European company formation. GI's ecosystem includes 13+ portfolio companies spanning engineered biology, life science tools & diagnostics, and therapeutics, with core AI capabilities through the Enable Medicine acquisition enabling AI-led generative biological search for drug discovery.
Differentiator
Problem solved
Functional benefit
Products and services
- Transformation Services
Quantifiable outcome
- Successfully created Ennovate Pharma with validated targets for autoimmune disease non-responders
- +3 more outcomes
Companies that use General Inception
Customer profileSegments3 records
Ideal customer profiles3 records
General Inception technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature4 records
General Inception partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Salk InstitutecoreSalk Institute scientist Sreekanth Chalasani leads an ARPA-H project with up to $41.3M funding. Collaborating institutions include Scripps Research, Duke University, MIT, UC San Diego, California Medical Innovations Institute, and SonoNeu (a General Inception spinout).
- Johnson & Johnson Innovation – JJDCcoreResolve M Therapeutics was created through a strategic collaboration between Johnson & Johnson Innovation – JJDC and General Inception, leveraging insights from Professor Nir Hacohen's lab at the Broad Institute.
- Institut PasteurcoreBiocellis announced equity partnership with General Inception and strategic collaboration with Institut Pasteur to accelerate bioluminescence-based diagnostics development and expand commercial reach of LuLISA technology.
- Enable MedicinecoreGeneral Inception acquired Enable Medicine and announced an equity and strategic partnership. The partnership provides GI greater access to Enable's biological data platform while Enable benefits from GI's drug development expertise and biotech ecosystem. The two companies first collaborated in 2023 to establish Ennovate Pharma.
- Professor James ZouminorAI pioneer in life sciences and medicine; member of Enable Medicine's Scientific Advisory Board. Provided commentary on the transformative potential of Enable's biological data indexing and interrogation technology.
- Ennovate PharmacoreJoint venture between General Inception and Enable Medicine established in 2023. Develops precision therapeutics for autoimmune and inflammatory diseases by leveraging biological atlases to identify and understand patient non-response to standard-of-care treatments. After 18 months, addressing refractory and non-responder populations with several validated targets.
- Broad InstitutecoreResearch collaboration with Professor Nir Hacohen's lab at the Broad Institute provided foundational science for Resolve M Therapeutics' pro-resolution platform for inflammatory diseases.
- PharmaceleracoreGeneral Inception established 2023 strategic alliance with Pharmacelera, where Pharmacelera became GI's strategic partner for AI-based drug discovery. GI's Chief Scientific Officer sits on Pharmacelera's Board of Directors. Pharmacelera has contributed to strengthening IP for several GI portfolio companies.
Scale indicators3 records
Recent moves7 records
Expansion highlights6 records
General Inception competitors and assessment
Company assessmentDirect peers
- IndieBio: IndieBio is a biotech accelerator that funds and incubates early-stage science startups, with programs in both San Francisco and New York. It is comparable to General Inception's deep-tech focus and venture creation model, though structured more as an accelerator than a long-term builder.
- Flagship Pioneering: Flagship Pioneering is the largest and most established biotech venture studio, originating companies like Moderna. It is the closest analog to General Inception's model of creating and incubating multiple biotech ventures from scientific founders, with comparable portfolio scale and pharma partnership intensity.
- MBC Biolabs: MBC Biolabs operates shared lab facilities and incubator programs for biotech startups in the San Francisco Bay Area. It represents a comparable biotech venture creation model focused on early-stage company formation with shared infrastructure — directly analogous to GIL'S Lab Services offering within General Inception.
- Petri: Petri is a biotech venture studio that partners with scientists to launch new companies. It shares General Inception's focus on company creation at the intersection of biology and technology, though Petri operates at smaller scale and earlier stage.
- Apollo Therapeutics: Apollo Therapeutics is a venture builder that creates and funds biotech companies from academic research, backed by pharma investors including AstraZeneca and GSK. Its pharma-backed venture building model closely mirrors General Inception's collaboration with J&J Innovation.
- BioGenerator: BioGenerator is a St. Louis-based biotech venture studio that creates and funds life sciences companies from academic research. Its model of company creation with operational support directly parallels General Inception's Igniter approach, though it operates regionally rather than globally.
Broad incumbents
- Evotec: Evotec is a global drug discovery and development company with a venture-building arm (e.g., Evotec's BRIDGE initiative) that co-creates biotech companies. As a much larger public company with broader CRO offerings, Evotec is an incumbent comparable to General Inception's biotech venture building activities.
- BridgeBio Pharma: BridgeBio operates multiple subsidiary biotechs targeting genetic diseases through a portfolio model. Its broader scope and public market status make it a comparable incumbent, with similar strategic use of subsidiary structures and a focus on advancing multiple programs in parallel.
- Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery company that combines proprietary data platforms with a portfolio approach to therapeutic development. Its use of generative AI and large biological datasets to accelerate drug discovery is comparable to General Inception's Enable Medicine platform strategy.
- Roivant Sciences: Roivant builds and operates multiple biotech subsidiaries (Vants) across therapeutic areas, using a hub-and-spoke model similar to GI's portfolio structure. While publicly traded and much larger, Roivant's approach to creating focused subsidiaries from scientific platforms is highly comparable to General Inception's portfolio strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
General Inception social profiles
Digital presenceGeneral Inception financial estimates
Financial estimateRevenue estimate
Valuation estimate
General Inception leadership team
Management profileNumber of profiles
Profiles4 records
General Inception subsidiaries and ownership
Company hierarchySubsidiaries5 records
General Inception funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
General Inception M&A and investment
M&A and investmentM&A1 record
Investments9 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about General Inception
What does General Inception do?
General Inception operates as a Deep Tech Venture Studio that co-founds science-based companies with extraordinary technical founders, providing business co-founding services that span talent sourcing, customer introductions, and funding access from idea through seed investment and beyond. Complementing venture creation, GI sells discrete professional services — Transformation Services (fractional executive leadership for turnarounds and growth), Fractional Finance (CFO-level finance and accounting support), and Lab Services / GIL'S (R&D operations across fibrosis, oncology, inflammation, and autoimmune disease) — to portfolio companies and external clients.
Is General Inception a public or private company?
General Inception is a private company. It is classified as venture growth investor backed and is currently operating.
When was General Inception founded?
General Inception was founded in 2020. It employs 11 to 50 people.
Where is General Inception based?
General Inception is headquartered in San Francisco, United States, in the North America region.
How does General Inception make money?
Two revenue lines are on record. Portfolio Company Returns are the primary driver. The others are services Revenue.
Who are General Inception's main competitors?
Direct peers on record are IndieBio, Flagship Pioneering, MBC Biolabs, Petri, Apollo Therapeutics and BioGenerator. Broad incumbents are Evotec, BridgeBio Pharma, Recursion Pharmaceuticals and Roivant Sciences.
Does General Inception have an API?
No public API is recorded for General Inception.
What industry is General Inception in?
General Inception's product category is Venture Studio / Biotech Incubation Services. Its primary akta.pro industry code is FSANAAAH, Venture Studios / Company Builders. Its NAICS code is 523940 and its SIC code is 8742.